First line treatment selection modifies disease course and long-term clinical outcomes in Mycobacter...
First line treatment selection modifies disease course and long-term clinical outcomes in Mycobacterium avium complex pulmonary disease
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
The combination of rifamycin (RFP), ethambutol (EB), and macrolides is currently the standard regimen for treatment of
Mycobacterium avium
complex pulmonary disease (MAC-PD). However, poor adherence to the standardized regimens recommended by current guidelines have been reported. We undertook a single-centred retrospective cohort study to ev...
Alternative Titles
Full title
First line treatment selection modifies disease course and long-term clinical outcomes in Mycobacterium avium complex pulmonary disease
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_3a2e1baa63ee4ff4a81f0ec6b2a4718d
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_3a2e1baa63ee4ff4a81f0ec6b2a4718d
Other Identifiers
ISSN
2045-2322
E-ISSN
2045-2322
DOI
10.1038/s41598-021-81025-w
